

Date: 31<sup>st</sup> July, 2020

To

The Manager – Listing,  
BSE Limited,  
P.J. Tower, Dalal Street,  
Mumbai – 400 001  
Scrip Code: 540359

**Subject: Outcome of Board Meeting and Results for Quarter and Financial year ended 31<sup>st</sup> March, 2020.**

Dear Sirs,

Further to our letter dated 24<sup>th</sup> July, 2020 and pursuant to the Regulation 33 and 30 of SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015 we wish to inform you that the Board of Directors of the Company in its meeting held today, i.e. 31<sup>st</sup> July, 2020, have considered and approved the following:

1. The Audited standalone financial results for the quarter and financial year ended 31<sup>st</sup> March, 2020.
2. Appointment of CS Samsad Alam Khan, Practicing Company Secretaries, (Membership No. A28719) as a Secretarial Auditor of the Company for Financial Year 2020-21.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015, we enclose herewith:


1. Audited Standalone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2020.
2. Independent Auditor's Report on the Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2020.

The Meeting of Board of Directors was commenced at 2.00 p.m. and concluded at 6.50 pm.

You are requested to take the same on your records.

Yours faithfully,

**For Parmax Pharma Limited**

  
**Yash J. Vora**  
Company Secretary



## Statement of Standalone Audited Results for the Quarter &amp; Financial year ended 31.03.2020

(in Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
	(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I.	Revenue from operations	43685011	69384878	32261325	209341081	120126358
II.	Other income	500846	91943	327820	977787	481988
III.	<b>Total Income (I+II)</b>	<b>44185857</b>	<b>69476821</b>	<b>32589145</b>	<b>210318868</b>	<b>120608346</b>
IV.	<b>Expenses</b>					
	(a) Cost of materials consumed	15572077	33830775	1958588	97936820	39233109
	(b) Purchase of stock-in-trade	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	10573541	2577986	-2335568	14722662	12174762
	(d) Employee benefits expense	6787577	7372508	5283443	29139115	20754610
	(e) Finance Costs	912815	116779	-48222	1273690	325496
	(f) Depreciation and amortisation expense	3712230	2170283	2559484	10071526	10302507
	(g) Other expenses	12443145	13239244	16345164	49868688	36836606
	<b>Total expenses (IV)</b>	<b>50001385</b>	<b>59307575</b>	<b>23762889</b>	<b>203012501</b>	<b>119627090</b>
V.	<b>Profit/(Loss) from operations before exceptional items and tax (I-IV)</b>	<b>-5815528</b>	<b>10169246</b>	<b>8826256</b>	<b>7306367</b>	<b>981256</b>
VI.	Exceptional Items	0	0	0	0	0
VII.	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>-5815528</b>	<b>10169246</b>	<b>8826256</b>	<b>7306367</b>	<b>981256</b>
VIII.	Tax expense:					
	(1) Current tax	1500000	0	750000	1500000	750000
	(2) Deferred tax	1519577	0	-555741	1519577	-555741
IX.	<b>Net Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-8835105</b>	<b>10169246</b>	<b>8631997</b>	<b>4286790</b>	<b>786997</b>
X.	<b>Profit/(loss) from discontinued operations</b>					
XI.	Tax expense of discontinued operations	0	0	0	0	0
XII.	<b>Profit/(loss) from Discontinued operations (after tax) (X-XI)</b>		0	0	0	0
XIII.	<b>Profit (Loss) for the period (IX+XII)</b>	<b>-8835105</b>	<b>10169246</b>	<b>8631997</b>	<b>4286790</b>	<b>786997</b>
XIV.	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0		0
	B. (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV.	<b>Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)</b>	<b>-8835105</b>	<b>10169246</b>	<b>8631997</b>	<b>4286790</b>	<b>786997</b>
XVI.	<b>Paid-up equity share capital (Face Value Rs 10)</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>
XVII.	<b>Earnings per share (for continuing operation &amp; discontinuing operation) (of Rs. 10/- each):</b>					
	(a) Basic	-2.36	2.72	2.31	1.15	0.21
	(b) Diluted					


Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

**Notes:**

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st July, 2020 and the same have been audited by the Stautory Auditors in compliance with Regulation 33 of SEBI (LODR) Reg., 2015. The
  2. The Company is operating in single (pharmaceutical) segment, hence above results are for single segment only.
  3. Statement of Audited Financial Results of the company for the Quarter and financial year ended 31st March, 2020, in the prescribed format under Schedule III of Companies Act, 2013
  4. The figures for the previous period have been regrouped wherever necessary.
- \* The Company has decided to gradually write off its all Preliminary and Pre-oprative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED



Alkesh Gosalia  
Managing Director (Finance and Operations)



Place Hadamtala (Rajkot)  
Date: 31.07.2020

## Statement of Assets and Liabilities as at 31.03.2020

Sr. No.	Particulars	As at 31.03.2020 (Audited)	As at 31.03.2019 (Audited)
I.	<b>Assets</b>		
1	<b>Non-current assets</b>		
	(a) Property, Plant and Equipment	96387453	49178115
	(b) Capital work-in-progress	-	33084385
	(c) Investment Property	-	0
	(d) Goodwill	-	0
	(e) Other Intangible assets	-	0
	(f) Intangible assets under development	-	0
	(g) Biological Assets other than bearer plants	-	0
	(h) Financial Assets	-	0
	(i) Investments	2006000	2006000
	(ii) Trade receivables	-	0
	(iii) Loans	1959560	1686813
	(i) Deferred tax assets (net)	-	794625
	(j) Other non-current assets	15845597	19806997
	<b>Total Non-Current Assets</b>	<b>116198610</b>	<b>106556934</b>
2	<b>Current assets</b>		
	(a) Inventories	27238627	39696524
	(b) Financial Assets	-	0
	(i) Investments	-	0
	(ii) Trade receivables	33046251	11460215
	(iii) Cash and cash equivalents	17674876	15674079
	(iv) Bank balances other than (iii) above	-	0
	(v) Loans	16483967	23505599
	(vi) Others (to be specified)	-	0
	(c) Current Tax Assets (Net)	-	0
	(d) Other current assets	-	0
	<b>Total Current Assets</b>	<b>94443722</b>	<b>90336417</b>
	<b>Total Assets</b>	<b>210642331</b>	<b>196893351</b>
II.	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity</b>		
	(a) Equity Share capital	44511500	44511500
	(b) Other Equity	6128446	1841656
	<b>Total Equity</b>	<b>50639946</b>	<b>46353156</b>
2	<b>LIABILITIES</b>		
i.	<b>Non-current liabilities</b>		0
	(a) Financial Liabilities	-	0
	(i) Borrowings	50335353	52386207
	(ii) Trade payables	-	0
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	0
	(b) Provisions	-	0
	(c) Deferred tax liabilities (Net)	724,952	0
	(d) Other non-current liabilities	-	0
	<b>Total of Non-Current Liabilities</b>	<b>51060305</b>	<b>98739363</b>
ii.	<b>Current liabilities</b>		
	(a) Financial Liabilities	-	0
	(i) Borrowings	-	0
	(ii) Trade payables	99240365	91855912
	(iii) Other financial liabilities (other than those specified in item (c))	-	0
	(b) Other current liabilities	2352366	3239479
	(c) Provisions	7349345	3058593
	(d) Current Tax Liabilities (Net)	-	0
	<b>Total of Current Liabilities</b>	<b>108942076</b>	<b>98153984</b>
	<b>Total Equity and Liabilities</b>	<b>210642331</b>	<b>196893351</b>

FOR, PARMAX PHARMA LIMITED



Alkesh Gosalia

Managing Director (Finance and Operations)



Place Hadamtala (Rajkot)

Date: 31.07.2020

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

## CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH , 2020

( Amt. Rs.)

PARTICULARS	Period Ended on 31/03/2020	Period Ended on 31/03/2019
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit After Extraordinary Item but Before Taxation:	7306367.16	981255.86
Adjustments for:		
Depreciation	10071526	10302507
Provision for Current Tax	1500000	750000
Provision for Deferred Tax Assets	1519577.02	-555740.517
Operating profit before Working Capital changes	15877893.16	10533762.86
Adjustments for changes in Working Capital:		
(Increase) / Decrease in Inventories	12457897	-7518298
(Increase) / Decrease in Trade & Other Receivables	-21586036.4	8259842
(Increase) / Decrease in Short term Loans and Advances	7021632.03	6138461.93
Increase / (Decrease) in Current Liabilities	6497340.36	-3520076.5
Increase / (Decrease) in Tax Provisions	4290751.7	575042
(Increase) / Decrease in Non Current Assets	3961400.08	-4314531
(Increase) / Decrease in Long term Loans & Advances	-272747	-906114
Cash generated from Operations	12370237.77	-1285673.57
<b>Net Cash from Operating activities</b>	<b>28248130.93</b>	<b>9248089.29</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	-23992643.15	-34142702
<b>Net Cash from / (Used in) Investing activities</b>	<b>-23992643.15</b>	<b>-34142702</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
Increase / (Decrease) in other Long Term Borrowings	-2254689.99	32991827.3
(Increase) / Decrease in Non Current Investment	0	-2000000
<b>Net Cash (Used in) Financing activities</b>	<b>-2254689.99</b>	<b>30991827.3</b>
<b>Net Increase in Cash &amp; Cash Equivalents (A + B + C)</b>	<b>2000800.79</b>	<b>6097217.59</b>
<b>Cash &amp; Cash Equivalents at the beginning of the year</b>	<b>15674081.59</b>	<b>9576862</b>
<b>Cash &amp; Cash Equivalents at the end of the year</b>	<b>17674882.38</b>	<b>15674081.59</b>

FOR, PARMAX PHARMA LIMITED



 Alkesh Gosalia  
 Managing Director (Finance and Operatic

 Place Hadamtala (Rajkot)  
 Date: 31.07.2020

Regd. Off. &amp; Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

**DECLARATION**

(Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015)

Pursuant to the proviso to regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended, We, Parmax Pharma Ltd, having its Registered office situated at Plot No. 20, Survey No. 52, Rajkot Gondal National Highway No. 27, Tal. Kotda Sangani, Dist. Rajkot 360311 Gujarat, do hereby declare and confirm that the Audit Report issued by Statutory Auditor of the Company M/s. B. A. Shah S. R. Mehta & Co., Chartered Accounts, (Firm Registration Number: 128796W) on the Annual Audited Standalone Financial Results for the year ended 31<sup>st</sup> March, 2020 is with Unmodified Opinion(s) and accordingly the statement on impact of audit qualification is not required to be given.

**For Parmax Pharma Limited**



**Keyur Vora**

**Chief Financial Officer**

Date: 31<sup>st</sup> July, 2020

Place: Hadamtala, Rajkot

# B A SHAH S R MEHTA & CO.

## Chartered Accountants

Partner  
**Malay B Shah**  
B.Com. F.C.A.  
M. No. 159526

Partner  
**Zarna M Shah**  
M.Com. F.C.A. DISA  
(Information Systems Audit)  
M. No. 144246

**Independent Auditor's Report on annual financial results of PARMAX PHARMA LIMITED pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

### INDEPENDENT AUDITOR'S REPORT

TO  
THE BOARD OF DIRECTORS OF  
PARMAX PHARMA LIMITED

#### Report on the Audit of the Standalone Financial Results

#### Opinion

We have audited the accompanying Statement of Financial Results of **PARMAX PHARMA LIMITED** ("the company") for the quarter and year ended **March 31, 2020** ("the Statement"), being submitted by Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the **quarter ended March 31, 2020** (date of the quarter end) as well as the **year to date** results for the period ended March 31, 2020



Head Office:  
209-Sapphire Complex, II<sup>nd</sup> Floor  
21/25-B New Jagnath Plot,  
Dr.Yagnik Road  
RAJKOT- 360 001  
(GUJARAT)

Branch Office:  
302-Vedant Complex,  
7/B Kalpana Society,  
C.G.Road, Navrangpura,  
AHMEDABAD - 380 009  
(GUJARAT)

Electronic Address:  
(O) 0281-2468261  
(F) 0281-3045432  
(M) 09427564149  
(E) [bassrmco.office@gmail.com](mailto:bassrmco.office@gmail.com)  
Or  
[mbshah\\_31@hotmail.com](mailto:mbshah_31@hotmail.com)

# B A SHAH S R MEHTA & Co.

## Chartered Accountants

Partner  
**Malay B Shah**  
B.Com. F.C.A.  
M. No. 159526

Partner  
**Zarna M Shah**  
M.Com. F.C.A. DISA  
(Information Systems Audit)  
M. No. 144246

### Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Impact of Pre-Operative Expenses written off on standalone financial statements:

\* In current year the management of Company has decided to write off its all Pre-operative expenses which are forming the part of Balance Sheet amounting to Rs. 1,98,06,997/- as on 01.04.2019 equally in 5 years. Accordingly Company has written off to tune of Rs. 9,90,350/- during this quarter under review and Total Pre-operative expenses Written off during the year under audit FY 2019-20 is Rs. 39,61,400 and same is forming part of Other Expenses in standalone audited financial statements forming part of this report.

Our opinion is not modified in respect of this matter.

### Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements.



Head Office:  
209-Sapphire Complex, II<sup>nd</sup> Floor  
21/25-B New Jagnath Plot,  
Dr.Yagnik Road  
RAJKOT- 360 001  
(GUJARAT)

Branch Office:  
302-Vedant Complex,  
7/B Kalpana Society,  
C.G.Road, Navrangpura,  
AHMEDABAD - 380 009  
(GUJARAT)

Electronic Address:  
(O) 0281-2468261  
(F) 0281-3045432  
(M) 09427564149  
(E) bassrmco.office@gmail.com  
Or  
[mbshah\\_31@hotmail.com](mailto:mbshah_31@hotmail.com)



# B A SHAH S R MEHTA & Co.

## Chartered Accountants

Partner

**Malay B Shah**

B.Com. F.C.A.

M. No. 159526

Partner

**Zarna M Shah**

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



#### Head Office:

209-Sapphire Complex, II<sup>nd</sup> Floor  
21/25-B New Jagnath Plot,  
Dr.Yagnik Road  
**RAJKOT- 360 001**  
(GUJARAT)

#### Branch Office:

302-Vedant Complex,  
7/B Kalpana Society,  
C.G.Road, Navrangpura,  
**AHMEDABAD - 380 009**  
(GUJARAT)

#### Electronic Address:

(O) 0281-2468261  
(F) 0281-3045432  
(M) 09427564149  
(E) [bassrmco.office@gmail.com](mailto:bassrmco.office@gmail.com)  
Or  
[mbshah\\_31@hotmail.com](mailto:mbshah_31@hotmail.com)

# B A SHAH S R MEHTA & Co.

## Chartered Accountants

Partner

**Malay B Shah**

B.Com. F.C.A.

M. No. 159526

Partner

**Zarna M Shah**

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **B A SHAH S R MEHTA & Co**

Chartered Accountants

FRN: 128796W



Malay B. Shah

M.No. 159526

UDIN: 20159526AAAAAN1796



Place: Rajkot

Date: 31.07.2020

Head Office:

209-Sapphire Complex, II<sup>nd</sup> Floor

21/25-B New Jagnath Plot,

Dr.Yagnik Road

RAJKOT- 360 001

(GUJARAT)

Branch Office:

302-Vedant Complex,

7/B Kalpana Society,

C.G.Road, Navrangpura,

AHMEDABAD - 380 009

(GUJARAT)

Electronic Address:

(O) 0281-2468261

(F) 0281-3045432

(M) 09427564149

(E) [bassrmco.office@gmail.com](mailto:bassrmco.office@gmail.com)

Or

[mbshah\\_31@hotmail.com](mailto:mbshah_31@hotmail.com)